AIP
MDGL icon

Arrowpoint Investment Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Arrowpoint Investment Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$624K Buy
1,192
+821
+221% +$392K 0.55% 34
2025
Q4 		$216K Sell
371
-421
-53% -$215K 0.03% 98
2025
Q3 		$363K Buy
+792
New +$295K 0.36% 55

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowpoint Investment Partners's MDGL Position: Q1 2026 in Review

Arrowpoint Investment Partners increased its Madrigal Pharmaceuticals (MDGL) stake by 221% in Q1 2026, buying an estimated $392K and bringing the position to 1,192 shares worth $624K. The position accounts for 0.55% of the portfolio, ranked #34.

Arrowpoint Investment Partners first reported a position in MDGL in Q3 2025 and has held it in 3 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Arrowpoint Investment Partners held 1,192 shares of Madrigal Pharmaceuticals worth $624K as of Q1 2026.
  • Arrowpoint Investment Partners bought 821 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $392K.
  • Madrigal Pharmaceuticals made up 0.55% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #34 holding.
  • Arrowpoint Investment Partners first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.